In Vivo Penetration of Experimentally Produced Clots by Monoclonal Antibodies

Summary

Antifibrin monoclonal antibodies show potential as clot targeting agents for diagnosis and possibly therapy in thrombotic disease. To be effective the antibody must bind to the fibrin component of the clot. The ability of two antifibrin mabs (NIB 1H10 and NIB 12B3) to penetrate occlusive clots in vivo was investigated Both mabs react with human fibrin but not with human fibrinogen nor with the fibrin or fibrinogen from the species used in this study.

Two heterologous animal (sheep and rabbit) thrombus models were used. Clots in both cases were made within isolated vein segments using a mixture of human and native fibrinogen. The clots in sheep veins were observed radiographically and found to be occlusive for a mean of 4.2 ± 2.2 days and thereafter appeared only partially occlusive. When targeted in their occlusive phase 131I labelled mab accumulated in the clot reaching a maximum ratio of 1.82 ± 0.42 when compared to counts in homologous sheep clots in the contralateral limb. It was confirmed in the rabbit jugular vein model that total occlusivity did not prevent antibody accumulation in the heterologous clot by injecting the fibrin specific mab IH10 and examining the clot excised after 1, 6 and 24 h using immunofluorescence. In a further series of similar experiments 125I labelled mab 1H10 was used and detected using autoradiography. Both sets of experiments indicated that penetration of occlusive clots by the antibody occurred and that considerable accumulation was present at 6 and 24 h.

The results indicate that a circulating antibody can readily gain access to experimentally produced clots in occluded veins.

Key words

Animal model - venous thrombosis - clot penetration - fibrin mab

• References

• 1 Lanza GM, Wallace KD, Scott MJ, Sheehan CK, Cacheris WP, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. A novel site targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94: 3334-40.
• 2 Procyk R, Kudryk B, Callender S, Blombäck B. Accessibility of epitopes on fibrin clots and fibrinogen gels. Blood 1991; 77: 1469-75.
• 3 Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Åslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
• 4 Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133-8.
• 5 von Kaulla KN, Fagleman D, Mueller H. Clot penetration and fibrin absorption of synthetic fibrinolytic compounds. In: Prog Chem Fibrinolysis and Thrombolysis Vol 1. Davidson JF, Samama MM, Desnoyers PC. Raven Press; New York: 1975: 45-54.
• 6 Blinc A, Planinsic G, Keber D, Jarh O, Lahajnar G, Zidansek A, Demsar F. Dependence of Blood Clot Lysis on the Mode of Transport of Urokinase into the Clot – A magnetic resonance imaging study in vitro. Thromb Haemost 1991; 65: 549-52.
• 7 Blinc A, Keber D, Lahajnar G, Stegnar M, Zidansek A, Demsar F. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots – a magnetic resonance imaging study in vitro. Thromb Haemost 1992; 68: 667-71.
• 8 Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994; 71: 230-5.
• 9 Collen D, Lijnen HR. Tissue-type plasminogen activator. Haemostasis 1986; 16 (Suppl. 03) 25-32.
• 10 Topol E. (GUSTO Investigators). An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-82.
• 11 Martin U, Kohnert U, Helleabrand K, Stern A, Popp F, Doerge L, Stegmeier K, Muller-Beckmann B, Fischer S. Effective thrombolysis by a recombinant escherichia coli – produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis. Fibrinolysis 1996; 10: 87-92.
• 12 Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of Reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis and Proteolysis 1997; 11: 129-36.
• 13 Smalling RWPJ. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 1997; 18 (suppl F): F11-6.
• 14 McEvoy FJ, Edgell TA, Webbon PM, Gaffney PJ. In vitro and in vivo penetration of experimentally produced clots by monoclonal antibodies. Fibrinolysis 1994; 08 (Suppl. 01) 187 (abstract).
• 15 Tymkewycz PM, Creighton-Kempsford LC, Gaffney PJ. Generation and characterisation of five monoclonal antibodies with high affinities for fibrin. Blood Coag Fibrinolysis 1993; 04: 211-22.
• 16 Edgell T, McEvoy F, Webbon P, Gaffney PJ. Monoclonal antibodies to human fibrin: Interaction with other animal fibrins. Thromb Haemost 1996; 75 (04) 595-9.
• 16a Gaffney PJ, Edgell TA, Stirk C, Thompson D, Melvin WT, Cederholm-Williams S, Marshall JM. A monoclonal antibody (mab) to fibrin. Delineation of the epitope on the COOH terminal of the Aa chain and its use in a soluble fibrin assay. Fibrinolysis and Proteolysis 1998; 12 (Suppl. 01) 68.
• 16b Raut S, Gaffney PJ. Evaluation of the fibrin binding profile of two anti-febrin monoclonal antibodies. Thromb Haemost 1996; 76 (04) 56-64.
• 19 Reay P. Use of N-bromosuccinimide for the iodination of proteins for radioimmunoassay. Ann Clin Biochem 1982; 19: 129-133.
• 20 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis; effect of molecular form and dose of activator, age of the thrombus and route of administration. J Clin Invest 1983; 71: 368-76.
• 21 Rabinov K, Paulin S. Röntgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
• 22 Rosebrough SF, Grossman ZD, McAfee JG, Kudryk BJ, Subramanian G, Ritter HC, Witanowski LS, Tillapaugh FG, Urrutia E, Zapf LC. Thrombus imaging with ¹¹¹indium and ¹³¹iodine labeled fibrin-specific monoclonal antibody and its F(ab’)2 and Fab fragments. J Nucl Med 1988; 29: 1212-22.
• 23 El Kouri D, Peltier P, Dupas B, Faivre A, Chaillou P, Moreau A, De Faucal P, Planchon B. ⁹⁹Tc^m – labelled anti-fibrin Fab’ fragment for evaluating the course of venous thrombosis in the rabbit. Nucl Med Comm 1994; 15: 50-7.
• 24 Schaible TF, Alavi A. Antifibrin scintigraphy in the diagnostic evaluation of acute deep venous thrombosis. Sem Nucl Med 1991; 21: 313-24.